Current Report Filing (8-k)
May 06 2019 - 4:09PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
M
ay
6,
2019
(Exact
Name of Registrant as Specified in its Charter)
Nevada
|
|
001-00100
|
|
87-0233535
|
(State
or Other
Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
6800
Broken Sound Parkway NW, Third Floor
Boca
Raton, FL 33487
|
(Address
of Principal Executive Office) (Zip Code)
|
Registrant’s
telephone number, including area code: (561) 961-1900
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
TXMD
|
The
Nasdaq Stock Market LLC
|
|
Item
2.02
|
Results
of Operations and Financial Condition.
|
On
May 6, 2019, TherapeuticsMD, Inc. (the "Company") issued a press release announcing its financial results for the first
quarter ended March 31, 2019. In addition, the Company will be using a slide presentation during its earnings conference call.
A copy of the press release and slide presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report
on Form 8-K and are incorporated herein by reference.
The
information in Item 2.02 of this Current Report on Form 8-K (including the exhibits) is furnished and shall not be deemed to be
“filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report on Form 8-K (including
the exhibits) shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities
Act”), or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation
language in the filing.
The
Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations
or any change in events, conditions, or circumstances on which any forward-looking statement is based.
|
Item
7.01
|
Regulation
FD Disclosure.
|
On
May 6, 2019, the Company issued a press release announcing the Company’s financial results for its first quarter ended March
31, 2019. In addition, the Company will be using a slide presentation during its earnings conference call. The information included
in this Item 7.01 and in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the
Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
|
Exhibits
|
Exhibit
Index
|
|
|
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release from TherapeuticsMD, Inc., dated May 6, 2019, entitled TherapeuticsMD Announces First Quarter 2019 Financial Results.
|
|
99.2
|
TherapeuticsMD,
Inc. Presentation dated May 6, 2019.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
May 6, 2019
|
THERAPEUTICSMD, INC.
|
|
|
|
By:
|
/s/ Daniel A. Cartwright
|
|
Name:
|
Daniel A. Cartwright
|
|
Title:
|
Chief Financial Officer
|
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Sep 2023 to Sep 2024